An 18 month outcome survey of the utilisation, accessibility and value of the Eastern Network for Kidney Inflammatory Disease (ENKID) virtual multidisciplinary team meeting (MDT). (UKKW 2025) - Jun 9, 2025 - Abstract #506; "34 responders reported receiving HCD approval for avacopan (74%), rituximab (56%), targeted-release budesonide (38%), belimumab (29%) and voclosporin (26%) (Figure 2). Overall 15 centres with 75 health care professional attendees suggests high accessibility; however, ongoing work will describe geographical access to ENKID and HCD use across the East of England, to ensure that discrepancies in access are identified and resolved. With further HCDs on the horizon for autoimmune kidney diseases, robust services and networks such as ENKID are essential to ensure specialist advice and equity of access to HCDs."
ANCA Vasculitis • Glomerulonephritis • Immunology • Inflammation • Inflammatory Arthritis • Nephrology • Renal Disease • Rheumatology • Vasculitis
|
|
Miss Olivia Kanka1; Dr Lucy Francis1; Dr Rachel B Jones, Dr Kevin Louden1; Dr Rona Smith1; Dr Lisa Willcocks1; Professor David Thomas1; Dr Barbara Thompson2; Dr Praveen Jeevaratnam2; Mrs Clare Morlidge2; Dr Ondrej Suchanek1
|